In short
A new clinical trial is underway to assess the effectiveness and safety of a novel drug called Human IgG4 Monoclonal Antibody Against LILRB2 (also known as IO-108) in combination with other treatments for patients with advanced liver cancer. This study, part of the MORPHEUS-Liver trial, aims to explore various immunotherapy-based combinations to improve outcomes for patients with this challenging disease.
At a glance
- Study Type
- Phase Ib/II, open-label, multicenter, randomized umbrella study
- Target Condition
- Advanced liver cancers (Hepatocellular Carcinoma)
- Main Objective
- Evaluate efficacy and safety of immunotherapy-based treatment combinations
- Primary Endpoint
- Objective Response Rate (ORR)
- Secondary Endpoints
- Progression-free survival, Overall survival, Duration of response
- Key Inclusion Criteria
- Adults with advanced HCC, no prior systemic treatment, Child-Pugh class A
- Key Exclusion Criteria
- Prior treatment with specific therapies, recent locoregional therapy, untreated varices
- Study Design
- Flexible design with multiple treatment arms, including IO-108 combinations
- Safety Monitoring
- Adverse events, laboratory abnormalities, vital signs, ECG parameters
What is LILRB2 and How Does This Antibody Work?
The HUMAN IGG4 MONOCLONAL ANTIBODY AGAINST LILRB2, also known as IO-108 or RO7791094, is an innovative treatment being studied for advanced liver cancer. This antibody targets a specific protein called LILRB2, which plays a role in the immune system's response to cancer cells.
LILRB2 stands for Leukocyte Immunoglobulin-Like Receptor B2. It's a protein found on certain immune cells that can sometimes prevent them from effectively fighting cancer. By blocking LILRB2, this antibody aims to enhance the immune system's ability to recognize and attack cancer cells.
Target Condition: Advanced Liver Cancer
This antibody is being studied specifically for patients with advanced liver cancers, particularly a type called hepatocellular carcinoma (HCC). HCC is the most common form of primary liver cancer, meaning cancer that starts in the liver rather than spreading there from another part of the body.
The study focuses on patients with: Locally advanced or metastatic HCC (cancer that has spread within the liver or to other parts of the body) Unresectable HCC (cancer that cannot be removed surgically) HCC that is not suitable for curative treatments or local therapies
Current Clinical Trial: MORPHEUS-Liver Study
The HUMAN IGG4 MONOCLONAL ANTIBODY AGAINST LILRB2 is currently being evaluated in a clinical trial called the MORPHEUS-Liver study. This is a Phase Ib/II study, which means it's testing both the safety and effectiveness of the treatment.
Key features of the study include: Open-label: Both patients and doctors know which treatment is being given Multicenter: Conducted at multiple hospitals or research centers Randomized: Patients are randomly assigned to different treatment groups Umbrella design: Multiple treatments are being tested within the same overall study structure
Eligibility Criteria for the Study
To participate in this study, patients must meet certain criteria. Some key eligibility requirements include:
- Age 18 or older
- Diagnosed with advanced HCC that can't be treated with surgery or local therapies
- No prior systemic treatment for HCC (this would be their first drug treatment for the cancer)
- Good overall health status (ECOG Performance Status of 0 or 1)
- Child-Pugh class A liver function (a measure of liver health)
- Life expectancy of at least 3 months
There are also certain conditions that would prevent a patient from participating, such as: Prior treatment with certain types of immunotherapy Recent treatment with other experimental drugs Untreated or high-risk bleeding from esophageal or stomach varices (enlarged veins) Ongoing significant side effects from previous cancer treatments
Treatment Arms and Combinations
In the MORPHEUS-Liver study, the HUMAN IGG4 MONOCLONAL ANTIBODY AGAINST LILRB2 (IO-108) is being tested in combination with other treatments. The study includes multiple "arms" or groups, each testing a different combination of drugs. Two of these arms involve IO-108:
- Experimental Arm 9: IO-108 in combination with other drugs
- Experimental Arm 10: IO-108 in a different combination
The exact details of these combinations are not provided in the available information. Other arms in the study are testing different immunotherapy combinations, which helps researchers compare the effectiveness of various approaches.
Study Objectives and Endpoints
The main goals of the MORPHEUS-Liver study are to evaluate:
- How well the treatments work (efficacy), primarily measured by:
- Objective Response Rate (ORR): The percentage of patients whose tumors shrink or disappear after treatment
- How safe the treatments are (safety), measured by:
- The occurrence and severity of side effects
- Changes in laboratory test results, vital signs, and ECG readings
Additional measures of efficacy (called secondary endpoints) include: Progression-Free Survival (PFS): How long patients live without their cancer getting worse Overall Survival (OS): How long patients live after starting treatment Duration of Response (DOR): How long tumors remain smaller after responding to treatment Disease Control: The percentage of patients whose cancer shrinks or stays stable
Potential Benefits and Considerations
The HUMAN IGG4 MONOCLONAL ANTIBODY AGAINST LILRB2 represents a new approach to treating advanced liver cancer. By enhancing the immune system's ability to fight cancer, it may offer hope for patients who have limited treatment options.
However, it's important to remember that this treatment is still experimental. The MORPHEUS-Liver study aims to determine: How effective the treatment is in shrinking tumors and prolonging survival What side effects may occur and how severe they might be How it compares to other immunotherapy combinations
Patients considering participating in this clinical trial should discuss the potential risks and benefits thoroughly with their healthcare team. The study's design allows for flexibility, meaning that if a particular treatment combination shows promise or raises concerns, adjustments can be made to optimize patient care and research outcomes.